Preview

Атеротромбоз

Расширенный поиск

ДЛИТЕЛЬНОСТЬ ДВОЙНОЙ АНТИТРОМБОЦИТАРНОЙ ТЕРАПИИ

https://doi.org/10.21518/2307-1109-2016-1-59-68

Полный текст:

Аннотация

В обзорной статье представлены современные данные по одному из ключевых вопросов современной кардиологии — продолжительности двойной антитромбоцитарной терапии (ДАТТ) у пациентов с перенесенным острым коронарным синдромом. Проведен анализ актуальных клинических рекомендаций, освещены результаты недавних клинических исследований и проведенных метаанализов. Представлена шкала оценки рисков ишемических и геморрагических событий, сформированная по результатам исследования DAPT.

Об авторе

О. Л. Барбараш
Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний, Кемерово; Кемеровская государственная медицинская академия
Россия
Доктор медицинских наук, профессор


Список литературы

1. Bhatt DL, Flather MD, Hacke W et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J am Coll Cardiol, 2007, 47: 1982-1988.

2. Sabouret P, Rushton-Smith SK, Kerneis M, Silvan J, Collet J-P, Montalescot G. Dual antiplatelet therapy: optimal timing, management, and duration. Eur Heart J — Cardiovascular Pharmacotherapy, 2015, 1: 198-204.

3. Montalescot G, Brieger D, Dalby A, Park S-J, Mehran R. Duration of Dual Antiplatelet Therapy after Coronary Stenting. JACC, 2015, 66(7): 832-847.

4. 2014 ESC/EACTS Guidelines on myocardial revascularization. The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) European Heart Journal Advance Access published August 29, 2014. European Heart Journal. doi:10.1093/eurheartj/ehu278.

5. Сutlip DE, Kereiakes DJ, Mauri L, Stoler R, Dauerman HL. Thrombotic complications associated with early and late nonadherence to dual antiplatelet therapy. J Am Coll Cardiol Intv, 2015, 8: 404-410. 6

6. . Maury L, Hsieh WH, Massaro JM, Ho KK, DAgostino R, Cultup D.E. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Eng J Med, 2007, 356: 1020-1029.

7. 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. JACC, 2014, December 23, 64(24):e139-228.

8. 2011 ACCF/AHA/SCAI Guideline for Percutaneus Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation, 2011, 124: 574-651.

9. The Clopidogrel in Unstable angina to prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med, 2001, 345: 494-502.

10. Yusuf S, Mehta SR, Zhao F et al. For the CURE Trial Investigators. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation, 2003, 107: 966-972.

11. Steinhubl SR, Berger PB, Mann JT3rd et al. For CREDO Investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA, 2002, 288: 2411-2420.

12. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2009, 361: 1045-1057.

13. Montalescot G, Bolognese L, Dudek D, Goldstein P, Hamm C, Tanguay JF, ten Berg JM, Miller DL, Costigan TM, Goedicke J, Silvain J, Angioli P, Legutko J, Niethammer M, Motovska Z, Jakubowski JA, Cayla G, Visconti LO, Vicaut E, Widimsky P. Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med, 2013, 369: 999-1010.

14. Lindholm D, Varenhorst C, Cannon CP, Harrington RA, Himmelmann A, Maya J, Husted S, Steg PG, Cornel JH, Storey RF, Stevens SR, Wallentin L, James SK. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. Eur Heart J, 2014, 35: 2083-2093.

15. Campo G, Tebaldi M, Vranckx P et al. Short-versus long-term duration of dual antiplatelet therapy in patients treated for in-stent restenosis: a PRODIGY trial substudy (Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia). J Am Coll Cardiol, 2014, 63: 506-512.

16. Gwon HC, Hahn J, Park KW, Song YB, Chae IH, Lim DC, Han KR, Choi JH, Choi SH, Kang HJ, Koo BK et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation, 2012, 125: 505-513.

17. Giustino G, Baber U, Sartori S, Mehran R, Mastoris I, Kini AS, Sharma S, Pocock S, Dangas GD. Duration of dual antiplatelet therapy after drugeluting stent impantation. J Am Coll Cardiol, 2015, 65(13): 1298-1310.

18. Price MJ. The optimal duration of dual antiplatelet therapy after drug-eluting stent implantation. Am Coll Cardiol, 2015, 65(13): 1311-1313.

19. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in postmyocardial infarction patients: nationwide real world data demonstrate the importance of long-term perspective. Eur Heart J. doi: 10.1093/eurheartj/ehu505.

20. Barbarash OL, Karetnikova VN, Kashtalap VV. The patient after myocardial infarction: how to reduce a risk of recurrent ischemic event? Cardiosomatics, 2015, 6(2): 12-19.

21. Waters DD, Schwartz GG, Olsson AG et al. Effects of atorvastatin on stroke in patients with unstable angina or non–Q-wave myocardial infarction: a myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) substudy. Circulation, 2002, 106: 1690-1695.

22. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM for the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med, 2004, 350(15): 1495-1504.

23. Mauri L, Kereiakes DJ, Yeh RW et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med, 2014, 371: 2155-2166.

24. Yeh RW, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MJ, Gershlick AH, Cutlip DE et al. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. JACC, 2015, 65(20): 2211-2221.

25. Bonaca MP, Bhatt D, Braunwald E, Cohen M, Steg PG, Storey RF, Held P, Sabatine MS, Jensen EC. Design and rationale for the prevention of cardiovascular events in patients with prior heart attack using ticagrelor compared to placebo on a background of aspirinthrombolysis in myocardial infarction 54 (PEGASUSTIMI 54) trial. Am Heart J, 2014, 167: 437-444.e5.

26. Bonaca MP, Bhatt D, Cohen M, Steg PG, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Ophuis TO, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS for the PEGASUSTIMI 54 Steering Committee and Investigators. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. Doi: 10.1056/NEJMoa1500857.

27. Ubell JA, Bonaca MC, Collet JP, Lincoff AM, Kereiakes DJ, Costa F, Lee CW, Mauri L et al. Long-term antiplatelaet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative metaanalysis of randomized trials. Eur Hear J, 2015. Doi: 10.1093/eurheartj/ehv443.

28. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal Advance Access published August 29, 2015. European Heart Journal. Doi:10.1093/eurheartj/ehv320.

29. Abu-Assi E, Raposeiras-Roubin S, Garcia-Acuna JM, Gonzalez-Juanatey JR. Bleeding risk stratification in an era of aggressive management of acute coronary syndromes. World J Cardiol, 2014, 6(11): 1140-1148.

30. Yeh R, Secemsky E, Kereiakes DJ, Normand SL, Gershlick AH, Cohen DJ. Individualizing treatment duration of dual antiplatelet therapy after percutaneous coronary intervention: an analysis from the DAPT study. In American Heart Association conference, (2015, November ), Orlando.

31. Rossello X, Pocock SJ, Julian DG. Long-Term Use of Cardiovascular Drugs: Challenges for Research and for Patient Care. J Am Coll Cardiol, 2015 Sep 15, 66(11): 1273-85. doi: 10.1016 /j.jacc.2015.07.018.


Для цитирования:


Барбараш О.Л. ДЛИТЕЛЬНОСТЬ ДВОЙНОЙ АНТИТРОМБОЦИТАРНОЙ ТЕРАПИИ. Атеротромбоз. 2016;(1):59-68. https://doi.org/10.21518/2307-1109-2016-1-59-68

For citation:


Barbarash O.L. DURATION OF DUAL ANTIPLATELET THERAPY. Atherothrombosis. 2016;(1):59-68. (In Russ.) https://doi.org/10.21518/2307-1109-2016-1-59-68

Просмотров: 646


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2307-1109 (Print)
ISSN 2658-5952 (Online)